NCT00632866View on ClinicalTrials.gov

Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2012

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

Hydroxychloroquine

Hydroxychloroquine : 200mg / day since 24 weeks

DRUG

Placebo

Placebo : 2cp/ day since 24 weeks

Trial Locations (1)

94275

Hopital Bicëtre, Le Kremlin-Bicêtre

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00632866 - Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter